Insider transactions

EDGAR

The Cigna Group

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
19 transactions, 229,533 shares
Sum of shares × price per share: 66,839,148.6792

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 86

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-03 Filed 2026-09-08Neville Everett Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)617284.05
175,258.85

Derived: shares × price per share. Exact value 175258.85.

5,053Direct (D) Yes
F1
  • F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2026.
Open filing 0001641142-26-000003 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-03Evanko Brian C Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $.01 Par Value
Acquired (A)3,1130—41,030Direct (D) No
F1
  • F1 These restricted shares vest in three equal annual installments beginning September 1, 2027.
Open filing 0001722909-26-000007 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-03Evanko Brian C Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock, $0.01 Par Value (6,716) — exercise price 281.1325
Acquired (A)6,7160—6,716Direct (D) No
F3
  • F3 This option vests in three equal annual installments beginning September 1, 2027.
Open filing 0001722909-26-000007 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-02Kurian George Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock, $.01 Par Value (108.6642)
Acquired (A)108.6642276.08
30,000.012336

Derived: shares × price per share. Exact value 30000.012336.

2,041.8523Direct (D) No
F1, F2
  • F1 Under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation (Deferral Plan), directors may elect to defer the payment of the cash and/or common stock portion of their retainers beyond the designated payment date. The phantom stock units described in Table II represent the voluntary deferral of a portion of the reporting person's cash retainer into the hypothetical stock fund under the Deferral Plan. Each phantom stock unit is the economic equivalent of one share of The Cigna Group's common stock and will be settled in cash.
  • F2 Includes 10.7387 phantom stock units acquired pursuant to a dividend reinvestment feature of the Deferral Plan.
Open filing 0001586813-26-000006 Read from the filing’s XML Dispute this row
2026-08-18 Filed 2026-08-20Jones Nicole S Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)2,677279.61
748,515.97

Derived: shares × price per share. Exact value 748515.97.

25,880Direct (D) Yes
F1
  • F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.
Open filing 0001492663-26-000003 Read from the filing’s XML Dispute this row
2026-08-06 Filed 2026-08-20Holgerson Bryan Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock, $.01 Par Value (0.9837)
Acquired (A)0.9837275.25
270.763425

Derived: shares × price per share. Exact value 270.763425.

944.6253Direct (D) No
F2
  • F2 Each phantom stock unit is the economic equivalent of one share of The Cigna Group's common stock and will be settled in cash in accordance with the terms of The Cigna Group Executive Deferred Compensation Plan. The reporting person may transfer his interests in The Cigna Group stock fund into an alternative investment fund.
Open filing 0002142615-26-000003 Read from the filing’s XML Dispute this row
2026-08-05 Filed 2026-08-06Jones Nicole S Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $.01 Par Value
Acquired (A)1,301192.02
249,818.02

Derived: shares × price per share. Exact value 249818.02.

28,557Direct (D) Yes
F1
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.
Open filing 0001739940-26-000067 Read from the filing’s XML Dispute this row
2026-08-05 Filed 2026-08-06Jones Nicole S Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock, $.01 Par Value (1,301) — exercise price 192.02
Disposed (D)1,3010—0Direct (D) Yes
F1, F3
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.
  • F3 This option was granted on February 26, 2020. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.
Open filing 0001739940-26-000067 Read from the filing’s XML Dispute this row
2026-08-04 Filed 2026-08-06Jones Nicole S Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $.01 Par Value
Acquired (A)14,045192.02
2,696,920.9

Derived: shares × price per share. Exact value 2696920.90.

46,692Direct (D) Yes
F1
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.
Open filing 0001739940-26-000067 Read from the filing’s XML Dispute this row
2026-08-04 Filed 2026-08-06Jones Nicole S Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)19,436276.27
5,369,583.72

Derived: shares × price per share. Exact value 5369583.72.

27,256Direct (D) Yes
F1
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.
Open filing 0001739940-26-000067 Read from the filing’s XML Dispute this row
2026-08-04 Filed 2026-08-06Jones Nicole S Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock, $.01 Par Value (14,045) — exercise price 192.02
Disposed (D)14,0450—1,301Direct (D) Yes
F1, F3
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.
  • F3 This option was granted on February 26, 2020. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.
Open filing 0001739940-26-000067 Read from the filing’s XML Dispute this row
2026-07-23 Filed 2026-08-20Holgerson Bryan Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock, $.01 Par Value (0.9458)
Acquired (A)0.9458286.29
270.773082

Derived: shares × price per share. Exact value 270.773082.

943.6416Direct (D) No
F2
  • F2 Each phantom stock unit is the economic equivalent of one share of The Cigna Group's common stock and will be settled in cash in accordance with the terms of The Cigna Group Executive Deferred Compensation Plan. The reporting person may transfer his interests in The Cigna Group stock fund into an alternative investment fund.
Open filing 0002142615-26-000003 Read from the filing’s XML Dispute this row
2026-07-09 Filed 2026-08-20Holgerson Bryan Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock, $.01 Par Value (0.8873)
Acquired (A)0.8873291.80
258.91414

Derived: shares × price per share. Exact value 258.914140.

942.6958Direct (D) No
F2
  • F2 Each phantom stock unit is the economic equivalent of one share of The Cigna Group's common stock and will be settled in cash in accordance with the terms of The Cigna Group Executive Deferred Compensation Plan. The reporting person may transfer his interests in The Cigna Group stock fund into an alternative investment fund.
Open filing 0002142615-26-000003 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-16Kates Jamie G Officer: Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $.01 Par Value
Acquired (A)899152.8947
137,452.3353

Derived: shares × price per share. Exact value 137452.3353.

3,267Direct (D) No— Open filing 0001739940-26-000047 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-16Kates Jamie G Officer: Chief Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)899298.612
268,452.188

Derived: shares × price per share. Exact value 268452.188.

2,368Direct (D) No— Open filing 0001739940-26-000047 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-16Kates Jamie G Officer: Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock, $.01 Par Value (899) — exercise price 152.8947
Disposed (D)8990—0Direct (D) No
F1
  • F1 This option was granted on February 28, 2018. The option vested in three equal annual installments starting on February 28, 2019.
Open filing 0001739940-26-000047 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-03Koka Durga Prasad Officer: EVP, Global CIO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock, $.01 Par Value
Disposed (D)729275.53
200,861.37

Derived: shares × price per share. Exact value 200861.37.

6,552Direct (D) No
F1
  • F1 Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.
Open filing 0001739940-26-000045 Read from the filing’s XML Dispute this row
2026-05-29 Filed 2026-06-02Kurian George Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Phantom Stock Units — underlying Common Stock, $.01 Par Value (108.1471)
Acquired (A)108.1471277.40
30,000.00554

Derived: shares × price per share. Exact value 30000.005540.

1,922.4494Direct (D) No
F1, F2
  • F1 Under the Deferred Compensation Plan of 2005 for Directors of Cigna Corporation (Deferral Plan), directors may elect to defer the payment of the cash and/or common stock portion of their retainers beyond the designated payment date. The phantom stock units described in Table II represent the voluntary deferral of a portion of the reporting person's cash retainer into the hypothetical stock fund under the Deferral Plan. Each phantom stock unit is the economic equivalent of one share of The Cigna Group's common stock and will be settled in cash.
  • F2 Includes 10.6351 phantom stock units acquired pursuant to a dividend reinvestment feature of the Deferral Plan.
Open filing 0001586813-26-000004 Read from the filing’s XML Dispute this row
2026-05-13 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $.01 Par Value
Acquired (A)15,458149.135
2,305,328.83

Derived: shares × price per share. Exact value 2305328.830.

49,795Direct (D) Yes
F1
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-13 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $.01 Par Value
Acquired (A)7,971197.35
1,573,076.85

Derived: shares × price per share. Exact value 1573076.85.

57,766Direct (D) Yes
F1
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-13 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock, $.01 Par Value (15,458) — exercise price 149.135
Disposed (D)15,4580—0Direct (D) Yes
F1, F16
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F16 This option was granted on February 28, 2017. The option vested in three equal annual installments starting on March 1, 2018.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-13 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock, $.01 Par Value (7,971) — exercise price 197.35
Disposed (D)7,9710—0Direct (D) Yes
F1, F17
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F17 This option was granted on February 28, 2018. The option vested in three equal annual installments starting on March 1, 2019.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $.01 Par Value
Acquired (A)103,595149.135
15,449,640.325

Derived: shares × price per share. Exact value 15449640.325.

150,696Direct (D) Yes
F1
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock, $.01 Par Value
Acquired (A)85,519197.35
16,877,174.65

Derived: shares × price per share. Exact value 16877174.65.

236,215Direct (D) Yes
F1
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)3,903286.832
1,119,505.296

Derived: shares × price per share. Exact value 1119505.296.

232,312Direct (D) Yes
F1, F2
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F2 Represents the weighted average price of the shares sold. The prices actually received ranged from $286.43 to $287.425 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)14,292287.9646
4,115,590.0632

Derived: shares × price per share. Exact value 4115590.0632.

218,020Direct (D) Yes
F1, F3
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F3 Represents the weighted average price of the shares sold. The prices actually received ranged from $287.43 to $288.42 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)13,839288.8544
3,997,456.0416

Derived: shares × price per share. Exact value 3997456.0416.

204,181Direct (D) Yes
F1, F4
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F4 Represents the weighted average price of the shares sold. The prices actually received ranged from $288.435 to $289.41 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)41,099290.0018
11,918,783.9782

Derived: shares × price per share. Exact value 11918783.9782.

163,082Direct (D) Yes
F1, F5
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F5 Represents the weighted average price of the shares sold. The prices actually received ranged from $289.435 to $290.43 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)13,732291.0056
3,996,088.8992

Derived: shares × price per share. Exact value 3996088.8992.

149,350Direct (D) Yes
F1, F6
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F6 Represents the weighted average price of the shares sold. The prices actually received ranged from $290.44 to $291.438 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)12,315291.9459
3,595,313.7585

Derived: shares × price per share. Exact value 3595313.7585.

137,035Direct (D) Yes
F1, F7
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F7 Represents the weighted average price of the shares sold. The prices actually received ranged from $291.44 to $292.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)7,861292.8776
2,302,310.8136

Derived: shares × price per share. Exact value 2302310.8136.

129,174Direct (D) Yes
F1, F8
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F8 Represents the weighted average price of the shares sold. The prices actually received ranged from $292.44 to $293.435 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)2,142293.919
629,574.498

Derived: shares × price per share. Exact value 629574.498.

127,032Direct (D) Yes
F1, F9
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F9 Represents the weighted average price of the shares sold. The prices actually received ranged from $293.46 to $294.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)38,487294.9798
11,352,887.5626

Derived: shares × price per share. Exact value 11352887.5626.

88,545Direct (D) Yes
F1, F10
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F10 Represents the weighted average price of the shares sold. The prices actually received ranged from $294.46 to $295.453 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)34,641295.9844
10,253,195.6004

Derived: shares × price per share. Exact value 10253195.6004.

53,904Direct (D) Yes
F1, F11
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F11 Represents the weighted average price of the shares sold. The prices actually received ranged from $295.46 to $296.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)2,017296.8357
598,717.6069

Derived: shares × price per share. Exact value 598717.6069.

51,887Direct (D) Yes
F1, F12
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F12 Represents the weighted average price of the shares sold. The prices actually received ranged from $296.46 to $297.45 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)15,319298.2398
4,568,735.4962

Derived: shares × price per share. Exact value 4568735.4962.

36,568Direct (D) Yes
F1, F13
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F13 Represents the weighted average price of the shares sold. The prices actually received ranged from $297.492 to $298.49 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)2,231298.5328
666,026.6768

Derived: shares × price per share. Exact value 666026.6768.

34,337Direct (D) Yes
F1, F14
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F14 Represents the weighted average price of the shares sold. The prices actually received ranged from $298.495 to $298.675 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock, $.01 Par Value (103,595) — exercise price 149.135
Disposed (D)103,5950—15,458Direct (D) Yes
F1, F16
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F16 This option was granted on February 28, 2017. The option vested in three equal annual installments starting on March 1, 2018.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Cordani David Director · Officer: Chairman CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock, $.01 Par Value (85,519) — exercise price 197.35
Disposed (D)85,5190—7,971Direct (D) Yes
F1, F17
  • F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • F17 This option was granted on February 28, 2018. The option vested in three equal annual installments starting on March 1, 2019.
Open filing 0001739940-26-000044 Read from the filing’s XML Dispute this row
2026-04-22 Filed 2026-04-24Kurian George Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $.01 Par Value
Acquired (A)7820—4,560Direct (D) No
F1
  • F1 The reporting person's economic interest in The Cigna Group securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of The Cigna Group stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than The Cigna Group stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for The Cigna Group and pages 51-52 and 118 of The Cigna Group's proxy statement filed with the SEC on March 13, 2026.
Open filing 0001739940-26-000032 Read from the filing’s XML Dispute this row
2026-04-22 Filed 2026-04-24MAZZARELLA KATHLEEN M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $.01 Par Value
Acquired (A)7820—6,891Direct (D) No— Open filing 0001739940-26-000033 Read from the filing’s XML Dispute this row
2026-04-22 Filed 2026-04-24Hennigan Michael J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $.01 Par Value
Acquired (A)7820—1,350Direct (D) No— Open filing 0001739940-26-000030 Read from the filing’s XML Dispute this row
2026-04-22 Filed 2026-04-24Hathi Neesha Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $.01 Par Value
Acquired (A)7820—4,151Direct (D) No— Open filing 0001739940-26-000035 Read from the filing’s XML Dispute this row
2026-04-22 Filed 2026-04-24WISEMAN ERIC C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $.01 Par Value
Acquired (A)7820—23,940Direct (D) No
F1
  • F1 The reporting person's economic interest in The Cigna Group securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of The Cigna Group stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than The Cigna Group stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for The Cigna Group and pages 51-52 and 118 of The Cigna Group's proxy statement filed with the SEC on March 13, 2026.
Open filing 0001739940-26-000028 Read from the filing’s XML Dispute this row
2026-04-22 Filed 2026-04-24ZARCONE DONNA F Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $.01 Par Value
Acquired (A)7820—27,517Direct (D) No
F1
  • F1 The reporting person's economic interest in The Cigna Group securities also includes hypothetical shares of common stock, the value of which is tied directly to the value of The Cigna Group stock. Under the rules of the Securities and Exchange Commission (SEC), Table I excludes these hypothetical shares because they are settled in cash, rather than The Cigna Group stock, upon separation from service. For more information regarding these securities, please see the reporting person's Section 16 filings for The Cigna Group and pages 51-52 and 118 of The Cigna Group's proxy statement filed with the SEC on March 13, 2026.
Open filing 0001739940-26-000034 Read from the filing’s XML Dispute this row
2026-04-22 Filed 2026-04-24Ross Kimberly A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $.01 Par Value
Acquired (A)7820—5,294Direct (D) No— Open filing 0001739940-26-000031 Read from the filing’s XML Dispute this row
2026-04-22 Filed 2026-04-24FOSS ERIC J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $.01 Par Value
Acquired (A)7820—36,696Direct (D) No— Open filing 0001739940-26-000037 Read from the filing’s XML Dispute this row
2026-04-22 Filed 2026-04-24Ozuah Philip Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $.01 Par Value
Acquired (A)7820—2,583Direct (D) No— Open filing 0001739940-26-000029 Read from the filing’s XML Dispute this row
2026-04-22 Filed 2026-04-24McClellan Mark B. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock, $.01 Par Value
Acquired (A)7820—6,891Direct (D) No— Open filing 0001739940-26-000036 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-03Neville Everett Officer: See Remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock, $.01 Par Value
Disposed (D)1,719288.91
496,636.29

Derived: shares × price per share. Exact value 496636.29.

5,670Direct (D) Yes
F5
  • F5 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2025.
Open filing 0001739940-26-000016 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

Showing 1–43 of 43

House members’ trades in this company, newest report first, as filed
MemberTransaction dateTypeAmountOwnerReport
Hon. Julie Johnson (TX32)2025-09-23Purchase$1,001 - $15,000JT2026-08-05
Hon. Julie Johnson (TX32)2025-09-23Sale$1,001 - $15,000JT2026-08-05
Hon. Jared Moskowitz (FL23)2026-03-23Sale$1,001 - $15,000DC2026-04-30
Hon. Jared Moskowitz (FL23)2026-03-23Sale$1,001 - $15,0002026-04-30
Hon. Gilbert Cisneros (CA31)2026-03-13Sale$1,001 - $15,0002026-04-07
Hon. Julie Johnson (TX32)2025-12-18Sale$1,001 - $15,000JT2026-01-15
Hon. Julia Letlow (LA05)2025-04-22Sale$1,001 - $15,0002026-01-13
Hon. Julia Letlow (LA05)2024-10-23Purchase$1,001 - $15,0002026-01-13
Hon. Gilbert Cisneros (CA31)2025-12-19Purchase$1,001 - $15,0002026-01-12
Hon. Gilbert Cisneros (CA31)2025-11-12Sale$1,001 - $15,0002025-12-15
Hon. Julie Johnson (TX32)2025-11-13Sale (partial)$1,001 - $15,000JT2025-12-11
Hon. Valerie Hoyle (OR04)2025-09-23Sale$1,001 - $15,000SP2025-10-10
Hon. Julie Johnson (TX32)2025-09-25Sale$1,001 - $15,000JT2025-10-07
Hon. Gilbert Cisneros (CA31)2025-08-05Sale (partial)$1,001 - $15,0002025-09-12
Hon. Valerie Hoyle (OR04)2024-10-29Purchase$1,001 - $15,000SP2025-09-12
Hon. Julie Johnson (TX32)2025-08-14Sale (partial)$1,001 - $15,000JT2025-09-11
Hon. Jared Moskowitz (FL23)2025-05-15Purchase$1,001 - $15,000DC2025-06-27
Hon. Jared Moskowitz (FL23)2025-05-15Purchase$1,001 - $15,0002025-06-27
Hon. Jefferson Shreve (IN06)2025-05-12Sale$15,001 - $50,0002025-06-22
Hon. Julie Johnson (TX32)2025-03-03Sale$1,001 - $15,000JT2025-04-14
Hon. Julie Johnson (TX32)2025-03-19Purchase$1,001 - $15,000JT2025-04-14
Hon. Rob Bresnahan (PA08)2025-02-25Sale$1,001 - $15,0002025-03-27
Hon. Jefferson Shreve (IN06)2025-02-24Purchase$15,001 - $50,0002025-03-09
Hon. Rob Bresnahan (PA08)2025-01-13Sale$1,001 - $15,000JT2025-02-13
Hon. Julie Johnson (TX32)2025-01-15Purchase$1,001 - $15,000JT2025-02-12
Hon. Gilbert Cisneros (CA31)2025-01-24Sale (partial)$1,001 - $15,0002025-02-11
Hon. Lois Frankel (FL22)2023-09-08Sale$15,001 - $50,0002023-10-10
Hon. Michael C. Burgess (TX26)2023-07-21Sale$15,001 - $50,0002023-08-08
Hon. Lois Frankel (FL22)2023-05-31Purchase$1,001 - $15,0002023-06-24
Hon. Lois Frankel (FL22)2023-04-05Purchase$1,001 - $15,0002023-04-28
Hon. Michael C. Burgess (TX26)2023-02-24Purchase$15,001 - $50,0002023-03-14
Hon. Thomas Suozzi (NY03)2021-06-04Sale (partial)$15,001 - $50,0002022-12-19
Hon. Thomas Suozzi (NY03)2021-10-05Sale (partial)$1,001 - $15,0002022-12-19
Hon. Thomas Suozzi (NY03)2019-11-18Sale (partial)$50,001 - $100,0002022-12-19
Hon. Lois Frankel (FL21)2022-11-02Sale (partial)$1,001 - $15,0002022-11-18
Hon. Lois Frankel (FL21)2022-05-18Sale (partial)$1,001 - $15,0002022-06-16
Hon. Michael C. Burgess (TX26)2021-11-19Sale (partial)$15,001 - $50,0002021-12-31
Hon. Thomas Suozzi (NY03)2020-01-09Purchase$15,001 - $50,0002021-09-23
Hon. Lois Frankel (FL21)2021-06-09Purchase$1,001 - $15,0002021-06-30
Mr. Peter Meijer (MI03)2021-02-16Sale$1,001 - $15,0002021-03-16
Hon. Lois Frankel (FL21)2021-01-21Sale (partial)$1,001 - $15,0002021-02-25
Hon. Gilbert Cisneros (CA39)2020-03-18Sale (partial)$1,001 - $15,0002020-04-16
Hon. Gerald E. Connolly (VA11)2019-12-18Sale$1,001 - $15,0002020-01-29

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Vanguard Capital Management Common Stock7.5119,814,43303/31/2026 Filed 2026-04-29SCHEDULE 13GOpen filing 0002100119-26-000303 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 8Open filing 0000102909-26-000482 Dispute this row
The Vanguard Group Common Stock10.0326,445,68902/27/2026 Filed 2026-03-05SCHEDULE 13G/AAmendment 7Open filing 0000102909-26-000340 Dispute this row
FMR LLC COMMON STOCK4.010,665,555.9609/30/2025 Filed 2025-11-05SCHEDULE 13G/AAmendment 1Open filing 0000315066-25-002698 Dispute this row
Abigail P. Johnson COMMON STOCK4.010,665,555.9609/30/2025 Filed 2025-11-05SCHEDULE 13G/AAmendment 1Open filing 0000315066-25-002698 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,769,310 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015185,692
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to The Cigna Group